Table 4 Fast and slow progressors in the SCarlet RoAD population
From: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
Variable, median score (Q1; Q3) | Change from baseline at week 104 (n = 310a) | |||||
|---|---|---|---|---|---|---|
Slow progressors (n = 202) | Fast progressors (n = 108) | |||||
Placebo (n = 70) | Gantenerumab 105 mg (n = 57) | Gantenerumab 225 mg (n = 75) | Placebo (n = 35) | Gantenerumab 105 mg (n = 47) | Gantenerumab 225 mg (n = 26) | |
Primary endpoint | ||||||
CDR-SB | 0.5 (0, 1.5) | 0.5 (0, 2) | 1.0 (0, 1.5) | 1.5 (0.5, 3) | 1.0 (0, 2.75) | 2.0 (1, 2.88) |
Secondary endpoints | ||||||
ADAS-Cog 13 | 3.34 (−1.41, 8.41) | 3.5 (−2.5, 6.25) | 3.33 (−0.34, 8.67) | 6.0 (2.34, 12.17) | 4.84 (1.5, 7.92) | 2.66 (0.67, 7.5) |
CANTAB | −1.43 (−2.52, −0.31) | −1.14 (−3, 0.97) | −0.99 (−3.22, 0.56) | −2.42 (−4.09, 0.07) | −1.31 (−3.27, 0.25) | −0.81 (−1.98, 0.69) |
FAQ | 1 (0, 5) | 1 (0, 7) | 2 (0, 6) | 5 (2.5, 8) | 6 (2, 8.5) | 4 (1, 9) |
MMSE | −1 (−4, 0) | −1 (−4, 0.25) | −2 (−3, 0) | −3.5 (−4.75, −2) | −3 (−4.5, 0) | −2 (−4, 0) |